biostudies-literatureHo MFNIDA NIH HHSNIAAA NIH HHS304-314https://www.ebi.ac.uk/biostudies/studies/S-EPMC11269006biostudies-literatureUnknown120Acamprosate is a Food and Drug Administration (FDA) approved medication for the treatment of alcohol use disorder (AUD). However, only a subset of patients achieves optimal treatment outcomes. Currently, no biological measures are utilized to predict response to acamprosate treatment. We applied our established pharmaco-omics informed genomics strategy to identify potential biomarkers associated with acamprosate treatment response. Specifically, our previous open-label acamprosate clinical trial recruited 442 patients with AUD who were treated with acamprosate for three months. We first performed proteomics using baseline plasma samples to identify potential biomarkers associated with acamprosate treatment outcomes. Next, we applied our established "proteomics-informed genome-wide associatBrain, behavior, and immunityIL17RB genetic variants are associated with acamprosate treatment response in patients with alcohol use disorder: A proteomics-informed genomics study.PMC11269006R01 DA057928R01 AA027486K01 AA028050P20 AA017830Skime MLi HCohan JSHo AMCoombes BJBiernacka JCroarkin PEOesterle TSHeider RMHo MFZhang CNgo QKarpyak VMWeinshilboum RMSkillon CTuncturk MMoon IfalseIL17RB genetic variants are associated with acamprosate treatment response in patients with alcohol use disorder: A proteomics-informed genomics study.Acamprosate is a Food and Drug Administration (FDA) approved medication for the treatment of alcohol use disorder (AUD). However, only a subset of patients achieves optimal treatment outcomes. Currently, no biological measures are utilized to predict response to acamprosate treatment. We applied our established pharmaco-omics informed genomics strategy to identify potential biomarkers associated with acamprosate treatment response. Specifically, our previous open-label acamprosate clinical trial recruited 442 patients with AUD who were treated with acamprosate for three months. We first performed proteomics using baseline plasma samples to identify potential biomarkers associated with acamprosate treatment outcomes. Next, we applied our established "proteomics-informed genome-wide associat2024-01-01T00:00:00Z2024 Aug2026-06-03T00:34:16.072Z2025-04-19T20:46:13.468ZS-EPMC112690063885276010.1016/j.bbi.2024.06.007